Highlights, Trends, Opportunities & Outlook
How The HealthTech Industry Is Entering A (Probable) Recession, And Ways Management Teams Can Navigate Newly Unchartered Waters
Outcome Capital shares their analysis and insights on pivotal trends and opportunities within the Pharma Contract Services sector.
Outcome Capital shares their analysis and insights on pivotal trends and opportunities within the Digital Health sector.
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the Medical Device sector.
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the biopharma sector. This segment is poised for significant growth, scientific advancement and consolidation.
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the life science consulting sector. This vibrant segment is poised for significant growth and consolidation.
Outcome Capital shares their views, insights and data on key strategic and financial trends within the Virtual Care, Population Health and Tech-Enabled Payor segments. These vibrant segment niches of the broader Digital Health industry are poised for significant investment and consolidation.
As a highly specialized life science advisory and investment banking firm, Outcome Capital looks to identify emerging trends that effect how researchers and clinicians understand, diagnose, and treat disease.
Outcome Capital sat down and spoke with Dr. Cathy Petti to get her perspective on the shortcomings of COVID diagnosis and how to carve out a stronger path for the future.
Outcome Capital sat down and spoke with Chuck Morrison to get his thoughts on the effects of the current COVID-19 pandemic on diagnostic transactional activity in 2020 and how best to weather the economic environment.
The In Vitro Diagnostic market values established companies with regulatory approval and market traction. This is demonstrated by premiums paid for acquisitions of companies that offer the opportunity to quickly capture market share and IPOs of companies with significant revenues.
This market update captures assets currently in development and recent partnering/in-licensing transactions which can catalyze development and improve valuation for companies.
The ophthalmology market values innovation approaches, demonstrated by premiums paid for acquisition of first-in-class therapies and public market support of ophthalmology gene therapy companies.
The cell-based therapy market will grow significantly, supported by recent clarity in the FDA pathway, improved clinical outcomes as well as market entry by big pharma.
Would you like to learn more about working with Outcome Capital or discuss your specific needs?